|
Gene: RAB9A |
Gene summary for RAB9A |
Gene summary. |
Gene information | Species | Human | Gene symbol | RAB9A | Gene ID | 9367 |
Gene name | RAB9A, member RAS oncogene family | |
Gene Alias | RAB9 | |
Cytomap | Xp22.2 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | A0A024RBV5 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9367 | RAB9A | LZE4T | Human | Esophagus | ESCC | 9.61e-11 | 3.49e-01 | 0.0811 |
9367 | RAB9A | LZE7T | Human | Esophagus | ESCC | 2.47e-08 | 5.35e-01 | 0.0667 |
9367 | RAB9A | LZE8T | Human | Esophagus | ESCC | 9.01e-14 | 5.78e-01 | 0.067 |
9367 | RAB9A | LZE20T | Human | Esophagus | ESCC | 9.40e-06 | 3.53e-01 | 0.0662 |
9367 | RAB9A | LZE22T | Human | Esophagus | ESCC | 2.05e-05 | 4.18e-01 | 0.068 |
9367 | RAB9A | LZE24T | Human | Esophagus | ESCC | 8.42e-16 | 3.61e-01 | 0.0596 |
9367 | RAB9A | LZE21T | Human | Esophagus | ESCC | 7.35e-04 | 4.50e-01 | 0.0655 |
9367 | RAB9A | LZE6T | Human | Esophagus | ESCC | 8.01e-12 | 9.50e-01 | 0.0845 |
9367 | RAB9A | P1T-E | Human | Esophagus | ESCC | 1.48e-05 | 5.61e-01 | 0.0875 |
9367 | RAB9A | P2T-E | Human | Esophagus | ESCC | 4.57e-37 | 7.77e-01 | 0.1177 |
9367 | RAB9A | P4T-E | Human | Esophagus | ESCC | 1.46e-20 | 7.33e-01 | 0.1323 |
9367 | RAB9A | P5T-E | Human | Esophagus | ESCC | 1.21e-19 | 3.31e-01 | 0.1327 |
9367 | RAB9A | P8T-E | Human | Esophagus | ESCC | 2.20e-39 | 9.12e-01 | 0.0889 |
9367 | RAB9A | P9T-E | Human | Esophagus | ESCC | 1.52e-17 | 2.35e-01 | 0.1131 |
9367 | RAB9A | P10T-E | Human | Esophagus | ESCC | 1.33e-22 | 1.63e-01 | 0.116 |
9367 | RAB9A | P11T-E | Human | Esophagus | ESCC | 7.60e-18 | 7.58e-01 | 0.1426 |
9367 | RAB9A | P12T-E | Human | Esophagus | ESCC | 5.98e-20 | 3.95e-01 | 0.1122 |
9367 | RAB9A | P15T-E | Human | Esophagus | ESCC | 8.74e-22 | 4.56e-01 | 0.1149 |
9367 | RAB9A | P16T-E | Human | Esophagus | ESCC | 3.96e-26 | 5.28e-01 | 0.1153 |
9367 | RAB9A | P17T-E | Human | Esophagus | ESCC | 1.19e-05 | 3.32e-01 | 0.1278 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00072659 | Oral cavity | OSCC | Ras protein signal transduction | 185/7305 | 337/18723 | 1.95e-09 | 4.60e-08 | 185 |
GO:00518176 | Oral cavity | OSCC | modulation of process of other organism involved in symbiotic interaction | 54/7305 | 81/18723 | 4.22e-07 | 6.25e-06 | 54 |
GO:00358218 | Oral cavity | OSCC | modulation of process of other organism | 64/7305 | 106/18723 | 6.70e-06 | 7.36e-05 | 64 |
GO:00421476 | Oral cavity | OSCC | retrograde transport, endosome to Golgi | 55/7305 | 91/18723 | 2.79e-05 | 2.59e-04 | 55 |
GO:001619714 | Oral cavity | LP | endosomal transport | 98/4623 | 230/18723 | 1.65e-09 | 7.50e-08 | 98 |
GO:001648214 | Oral cavity | LP | cytosolic transport | 69/4623 | 168/18723 | 2.03e-06 | 4.65e-05 | 69 |
GO:005181713 | Oral cavity | LP | modulation of process of other organism involved in symbiotic interaction | 35/4623 | 81/18723 | 1.97e-04 | 2.16e-03 | 35 |
GO:000726515 | Oral cavity | LP | Ras protein signal transduction | 109/4623 | 337/18723 | 8.44e-04 | 7.36e-03 | 109 |
GO:003582113 | Oral cavity | LP | modulation of process of other organism | 41/4623 | 106/18723 | 9.70e-04 | 8.20e-03 | 41 |
GO:004214713 | Oral cavity | LP | retrograde transport, endosome to Golgi | 36/4623 | 91/18723 | 1.20e-03 | 9.67e-03 | 36 |
GO:00072658 | Prostate | BPH | Ras protein signal transduction | 101/3107 | 337/18723 | 5.64e-10 | 2.79e-08 | 101 |
GO:00164828 | Prostate | BPH | cytosolic transport | 51/3107 | 168/18723 | 6.56e-06 | 9.53e-05 | 51 |
GO:00161978 | Prostate | BPH | endosomal transport | 62/3107 | 230/18723 | 4.54e-05 | 4.77e-04 | 62 |
GO:19035324 | Prostate | BPH | positive regulation of secretion by cell | 62/3107 | 282/18723 | 1.07e-02 | 4.45e-02 | 62 |
GO:00518175 | Prostate | BPH | modulation of process of other organism involved in symbiotic interaction | 22/3107 | 81/18723 | 1.10e-02 | 4.53e-02 | 22 |
GO:00421475 | Prostate | BPH | retrograde transport, endosome to Golgi | 24/3107 | 91/18723 | 1.19e-02 | 4.82e-02 | 24 |
GO:000726514 | Prostate | Tumor | Ras protein signal transduction | 101/3246 | 337/18723 | 6.29e-09 | 2.44e-07 | 101 |
GO:001648213 | Prostate | Tumor | cytosolic transport | 54/3246 | 168/18723 | 2.01e-06 | 3.46e-05 | 54 |
GO:001619713 | Prostate | Tumor | endosomal transport | 62/3246 | 230/18723 | 1.65e-04 | 1.47e-03 | 62 |
GO:005181712 | Prostate | Tumor | modulation of process of other organism involved in symbiotic interaction | 27/3246 | 81/18723 | 3.57e-04 | 2.81e-03 | 27 |
Page: 1 2 3 4 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa051629 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
hsa05132310 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa0516213 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
hsa0513222 | Liver | Cirrhotic | Salmonella infection | 121/2530 | 249/8465 | 2.47e-10 | 5.13e-09 | 3.16e-09 | 121 |
hsa0513232 | Liver | Cirrhotic | Salmonella infection | 121/2530 | 249/8465 | 2.47e-10 | 5.13e-09 | 3.16e-09 | 121 |
hsa0513242 | Liver | HCC | Salmonella infection | 178/4020 | 249/8465 | 5.90e-15 | 1.98e-13 | 1.10e-13 | 178 |
hsa0513252 | Liver | HCC | Salmonella infection | 178/4020 | 249/8465 | 5.90e-15 | 1.98e-13 | 1.10e-13 | 178 |
hsa0513230 | Oral cavity | OSCC | Salmonella infection | 174/3704 | 249/8465 | 2.67e-17 | 1.49e-15 | 7.58e-16 | 174 |
hsa051628 | Oral cavity | OSCC | Measles | 90/3704 | 139/8465 | 4.10e-07 | 2.50e-06 | 1.27e-06 | 90 |
hsa05132114 | Oral cavity | OSCC | Salmonella infection | 174/3704 | 249/8465 | 2.67e-17 | 1.49e-15 | 7.58e-16 | 174 |
hsa0516212 | Oral cavity | OSCC | Measles | 90/3704 | 139/8465 | 4.10e-07 | 2.50e-06 | 1.27e-06 | 90 |
hsa05132210 | Oral cavity | LP | Salmonella infection | 128/2418 | 249/8465 | 1.17e-14 | 2.79e-13 | 1.80e-13 | 128 |
hsa0516221 | Oral cavity | LP | Measles | 59/2418 | 139/8465 | 2.90e-04 | 1.60e-03 | 1.03e-03 | 59 |
hsa0513238 | Oral cavity | LP | Salmonella infection | 128/2418 | 249/8465 | 1.17e-14 | 2.79e-13 | 1.80e-13 | 128 |
hsa0516231 | Oral cavity | LP | Measles | 59/2418 | 139/8465 | 2.90e-04 | 1.60e-03 | 1.03e-03 | 59 |
hsa0513228 | Prostate | BPH | Salmonella infection | 99/1718 | 249/8465 | 7.26e-13 | 1.50e-11 | 9.27e-12 | 99 |
hsa051624 | Prostate | BPH | Measles | 42/1718 | 139/8465 | 3.35e-03 | 1.23e-02 | 7.61e-03 | 42 |
hsa05132113 | Prostate | BPH | Salmonella infection | 99/1718 | 249/8465 | 7.26e-13 | 1.50e-11 | 9.27e-12 | 99 |
hsa0516211 | Prostate | BPH | Measles | 42/1718 | 139/8465 | 3.35e-03 | 1.23e-02 | 7.61e-03 | 42 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RAB9A | SNV | Missense_Mutation | c.142G>T | p.Asp48Tyr | p.D48Y | P51151 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD | |
RAB9A | SNV | Missense_Mutation | c.509G>A | p.Arg170Gln | p.R170Q | P51151 | protein_coding | tolerated(0.19) | benign(0.111) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD | |
RAB9A | SNV | Missense_Mutation | c.391N>T | p.Arg131Trp | p.R131W | P51151 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
RAB9A | insertion | Frame_Shift_Ins | novel | c.169_170insATCTCAAAAG | p.Thr57AsnfsTer28 | p.T57Nfs*28 | P51151 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
RAB9A | SNV | Missense_Mutation | c.127N>A | p.Glu43Lys | p.E43K | P51151 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
RAB9A | SNV | Missense_Mutation | c.201N>T | p.Glu67Asp | p.E67D | P51151 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
RAB9A | SNV | Missense_Mutation | c.509N>A | p.Arg170Gln | p.R170Q | P51151 | protein_coding | tolerated(0.19) | benign(0.111) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
RAB9A | SNV | Missense_Mutation | novel | c.77N>T | p.Arg26Ile | p.R26I | P51151 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RAB9A | SNV | Missense_Mutation | c.509N>A | p.Arg170Gln | p.R170Q | P51151 | protein_coding | tolerated(0.19) | benign(0.111) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
RAB9A | SNV | Missense_Mutation | c.509N>A | p.Arg170Gln | p.R170Q | P51151 | protein_coding | tolerated(0.19) | benign(0.111) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9367 | RAB9A | ENZYME, DRUGGABLE GENOME | NSC-234945 | CHEMBL260311 | ||
9367 | RAB9A | ENZYME, DRUGGABLE GENOME | CID 838877 | CHEMBL405317 | ||
9367 | RAB9A | ENZYME, DRUGGABLE GENOME | TDR77585 | CHEMBL1333386 | ||
9367 | RAB9A | ENZYME, DRUGGABLE GENOME | DNDI1417031 | CHEMBL1333049 | ||
9367 | RAB9A | ENZYME, DRUGGABLE GENOME | CID 660258 | CHEMBL259805 | ||
9367 | RAB9A | ENZYME, DRUGGABLE GENOME | 2-AMINO-ANTHRAQUINONE | CHEMBL84685 | ||
9367 | RAB9A | ENZYME, DRUGGABLE GENOME | CID 887167 | CHEMBL260342 | ||
9367 | RAB9A | ENZYME, DRUGGABLE GENOME | 7-HYDROXY ISOFLAVONE | 7-HYDROXY ISOFLAVONE | ||
9367 | RAB9A | ENZYME, DRUGGABLE GENOME | LASSBIO-123 | CHEMBL573111 | ||
9367 | RAB9A | ENZYME, DRUGGABLE GENOME | VU0080241 | CHEMBL477396 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |